TCM

TCG Crossover Management Portfolio holdings

AUM $4.16B Turnover 31.15%
1-Year Est. Return 983.43%
This Fund
S&P 500
This Quarter Est. Return
-4.16%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$249M
AUM Growth
+$35.5M
Cap. Flow
+$55.3M
Cap. Flow %
22.2%
Top 10 Hldgs %
78.83%
Holding
20
New
5
Increased
7
Reduced
2
Closed
–
Avg Time Held
0.2 years
Top 10 Avg Time Held
0.2 years
Top 20 Avg Time Held
0.2 years

Top Buys

Rank Stock Value
1
GERN icon
Geron
GERN
+$15.9M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$11.5M
3
TNGX icon
Tango Therapeutics
TNGX
+$10.9M
4
KURA icon
Kura Oncology
KURA
+$7.31M
5
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
+$2.25M

Top Sells

Rank Stock Value
1
ALPN icon
Alpine Immune Sciences Inc
ALPN
+$1.18M
2
DNTH icon
Dianthus Therapeutics
DNTH
+$335K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ISEE
1
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$42.4M 17.01%
2,516,920
+775,692
+45% +$11.5M
2021 Q4
1 quarter
VRDN icon
2
Viridian Therapeutics
VRDN
$2.08B
$24.3M 9.75%
1,314,000
– –
2021 Q4
1 quarter
COGT icon
3
Cogent Biosciences
COGT
$4.88B
$22.3M 8.96%
2,981,042
+231,005
+8% +$1.61M
2021 Q4
1 quarter
ACRS icon
4
Aclaris Therapeutics
ACRS
$498M
$19.7M 7.92%
1,144,939
+62,726
+6% +$856K
2021 Q4
1 quarter
GERN icon
5
Geron
GERN
$765M
$19.4M 7.8%
+14,285,715
New +$15.9M
2022 Q1
0 quarters
CBAY icon
6
DELISTED
Cymabay Therapeutics
CBAY
$18.4M 7.37%
5,905,400
– –
2021 Q4
1 quarter
JBIO icon
7
Jade Biosciences
JBIO
$855M
$16.3M 6.55%
25,416
+1,035
+4% +$402K
2021 Q4
1 quarter
KDNY
8
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$14.4M 5.79%
882,353
– –
2021 Q4
1 quarter
TYRA icon
9
Tyra Biosciences
TYRA
$1.29B
$9.59M 3.85%
896,418
+45,968
+5% +$546K
2021 Q4
1 quarter
TNGX icon
10
Tango Therapeutics
TNGX
$3.74B
$9.51M 3.82%
+1,254,500
New +$10.9M
2022 Q1
0 quarters
ALPN icon
11
DELISTED
Alpine Immune Sciences Inc
ALPN
$9.28M 3.72%
1,034,222
-135,990
-12% -$1.18M
2021 Q4
1 quarter
KURA icon
12
Kura Oncology
KURA
$855M
$8.14M 3.27%
+506,423
New +$7.31M
2022 Q1
0 quarters
MRUS icon
13
DELISTED
Merus
MRUS
$7.93M 3.18%
300,000
+75,000
+33% +$2.01M
2021 Q4
1 quarter
AKUS
14
DELISTED
Akouos Inc
AKUS
$6.41M 2.57%
1,350,006
+304,791
+29% +$1.79M
2021 Q4
1 quarter
DNTH icon
15
Dianthus Therapeutics
DNTH
$4.18B
$6.16M 2.47%
132,758
-6,131
-4% -$335K
2021 Q4
1 quarter
TRDA icon
16
Entrada Therapeutics
TRDA
$177M
$6.13M 2.46%
663,694
– –
2021 Q4
1 quarter
ZLAB icon
17
Zai Lab
ZLAB
$2.53B
$4.18M 1.68%
95,000
– –
2021 Q4
1 quarter
PRDS
18
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$1.65M 0.66%
+229,100
New +$2.25M
2022 Q1
0 quarters
ANAB icon
19
AnaptysBio
ANAB
$1.4B
$1.45M 0.58%
+58,515
New +$1.77M
2022 Q1
0 quarters
ELEV icon
20
DELISTED
Elevation Oncology
ELEV
$1.4M 0.56%
555,000
– –
2021 Q4
1 quarter

Similar funds

GCM
Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return
CIC
Chilton Investment Company Stamford, Connecticut $4.17B AUM 1.75% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $4.15B AUM 31.06% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $4.15B AUM
CAM
Crake Asset Management London, United Kingdom $4.18B AUM 13.97% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $4.14B AUM 21.49% 1-Year Est. Return
CCMIC
Cardinal Capital Management Inc (Canada) Winnipeg, Manitoba, Canada $4.13B AUM 31.23% 1-Year Est. Return

TCG Crossover Management's Q1 2022 Portfolio in Review

As of Q1 2022, TCG Crossover Management held 20 positions worth $249M, up 17% from $214M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

TCG Crossover Management deployed $55.3M of net new capital in Q1 2022, opening 5 new positions and adding to 7 existing holdings. Its largest new stake was Geron: 14,285,715 shares worth $19.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Alpine Immune Sciences Inc, an estimated $1.18M trimmed.

  • TCG Crossover Management's largest Q1 2022 buy was Geron: 14,285,715 shares worth $19.4M.
  • TCG Crossover Management added most to IVERIC bio, Inc. Common Stock in Q1 2022, an estimated $11.5M increase.
  • TCG Crossover Management's biggest Q1 2022 reduction was Alpine Immune Sciences Inc, cutting an estimated $1.18M.
  • TCG Crossover Management's ten largest holdings make up 79% of its $249M portfolio in Q1 2022.
  • TCG Crossover Management opened 5 new positions and closed 0 in Q1 2022.
  • TCG Crossover Management's portfolio value rose 17% quarter-over-quarter to $249M.

Based on TCG Crossover Management's 13F filing for Q1 2022, filed 16 May 2022.